Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

European submission to broaden label for Arzerra to include first-line CLL

Oct. 7, 2013

Heat Biologics files IND for HS-410 in bladder cancer

Oct. 3, 2013

Scancell provides update on its drug discovery pipeline

Oct. 3, 2013

Phase I/II trial of Mologen's renal cancer vaccine meets primary endpoints

Oct. 2, 2013

FDA grants accelerated approval of new indication for Perjeta

Oct. 2, 2013

MEDI-4736 treatment results in significant tumor suppression

Oct. 2, 2013

New French biotechnology company formed to develop MAb for ovarian cancer

Oct. 2, 2013

Results of phase III trial demonstrate improvements in PFS and PSA responses with ipilimumab

Oct. 1, 2013

Etubics receives SBIR grant for breast cancer immunotherapeutic

Oct. 1, 2013

Phase I results show promising oncolytic activity for the anti-HB-EGF antibody U3-1565

Sep. 30, 2013

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...